Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents

Nicolò Pipitone, Ignazio Olivieri, C. Salvarani

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume30
Issue numberSUPPL. 70
Publication statusPublished - 2012

Fingerprint

Biological Factors
Rheumatology
Vasculitis
Cogan Syndrome
Off-Label Use
Takayasu Arteritis
Giant Cell Arteritis
Biological Therapy
Therapeutics
Marketing

Keywords

  • Biologic agents
  • Large-vessel vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. / Pipitone, Nicolò; Olivieri, Ignazio; Salvarani, C.

In: Clinical and Experimental Rheumatology, Vol. 30, No. SUPPL. 70, 2012.

Research output: Contribution to journalArticle

@article{4130617c4ade449eb84df507ba7ba4a0,
title = "Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents",
abstract = "Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Beh{\cc}et's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.",
keywords = "Biologic agents, Large-vessel vasculitis",
author = "Nicol{\`o} Pipitone and Ignazio Olivieri and C. Salvarani",
year = "2012",
language = "English",
volume = "30",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "SUPPL. 70",

}

TY - JOUR

T1 - Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents

AU - Pipitone, Nicolò

AU - Olivieri, Ignazio

AU - Salvarani, C.

PY - 2012

Y1 - 2012

N2 - Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

AB - Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

KW - Biologic agents

KW - Large-vessel vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84863759339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863759339&partnerID=8YFLogxK

M3 - Article

VL - 30

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - SUPPL. 70

ER -